2012 Q3 Form 10-Q Financial Statement
#000110465912056527 Filed on August 09, 2012
Income Statement
| Concept | 2012 Q3 | 2012 Q2 | 2011 Q2 |
|---|---|---|---|
| Revenue | $3.113M | $2.009M | $1.952M |
| YoY Change | 31.74% | 2.92% | -33.83% |
| Cost Of Revenue | $3.010M | $1.870M | $1.940M |
| YoY Change | 29.74% | -3.61% | 12.14% |
| Gross Profit | $110.0K | $140.0K | $10.00K |
| YoY Change | 120.0% | 1300.0% | -99.18% |
| Gross Profit Margin | 3.53% | 6.97% | 0.51% |
| Selling, General & Admin | $2.840M | $2.220M | $2.240M |
| YoY Change | 25.11% | -0.89% | -13.51% |
| % of Gross Profit | 2581.82% | 1585.71% | 22400.0% |
| Research & Development | $11.77M | $11.11M | $7.169M |
| YoY Change | 36.94% | 55.03% | -1.25% |
| % of Gross Profit | 10699.09% | 7938.57% | 71690.0% |
| Depreciation & Amortization | $770.0K | $820.0K | $1.060M |
| YoY Change | -36.89% | -22.64% | -22.06% |
| % of Gross Profit | 700.0% | 585.71% | 10600.0% |
| Operating Expenses | $11.77M | $11.11M | $7.169M |
| YoY Change | 36.94% | 55.03% | -31.79% |
| Operating Profit | -$14.75M | -$13.49M | -$9.881M |
| YoY Change | 28.52% | 36.5% | 6.36% |
| Interest Expense | $381.0K | $411.0K | $434.0K |
| YoY Change | -13.01% | -5.3% | -280.83% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $105.0K | $79.00K | |
| YoY Change | -27.08% | ||
| Pretax Income | -$15.03M | -$13.77M | -$10.24M |
| YoY Change | 27.7% | 34.47% | 7.45% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$15.03M | -$13.77M | -$10.24M |
| YoY Change | 27.7% | 34.47% | 7.45% |
| Net Earnings / Revenue | -482.81% | -685.42% | -524.59% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$3.795M | -$3.513M | -$4.096M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 59.29M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2012 Q3 | 2012 Q2 | 2011 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $77.62M | $78.70M | $71.20M |
| YoY Change | 23.59% | 10.53% | 8.21% |
| Cash & Equivalents | $23.19M | $18.56M | $10.80M |
| Short-Term Investments | $54.43M | $60.10M | $60.40M |
| Other Short-Term Assets | $1.200M | $1.700M | $1.900M |
| YoY Change | -14.29% | -10.53% | 11.76% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $0.00 | $100.0K | $200.0K |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $78.81M | $80.40M | $73.30M |
| YoY Change | 22.41% | 9.69% | 7.32% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $7.566M | $8.000M | $10.00M |
| YoY Change | -20.36% | -20.0% | -9.09% |
| Goodwill | $8.965M | ||
| YoY Change | |||
| Intangibles | $24.09M | ||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $409.0K | $400.0K | $400.0K |
| YoY Change | 36.33% | 0.0% | -92.86% |
| Total Long-Term Assets | $41.03M | $41.73M | $45.20M |
| YoY Change | -6.9% | -7.68% | -15.2% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $78.81M | $80.40M | $73.30M |
| Total Long-Term Assets | $41.03M | $41.73M | $45.20M |
| Total Assets | $119.8M | $122.1M | $118.5M |
| YoY Change | 10.5% | 3.06% | -2.55% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.281M | $400.0K | $500.0K |
| YoY Change | 156.2% | -20.0% | -54.55% |
| Accrued Expenses | $8.157M | $6.600M | $4.400M |
| YoY Change | 35.95% | 50.0% | 7.32% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $5.300M | $5.300M | $5.000M |
| YoY Change | 29.27% | 6.0% | -58.33% |
| Total Short-Term Liabilities | $15.13M | $12.58M | $10.40M |
| YoY Change | 40.39% | 20.95% | -56.12% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $7.300M | $8.600M | $10.10M |
| YoY Change | -33.64% | -14.85% | |
| Other Long-Term Liabilities | $6.365M | $6.400M | $6.000M |
| YoY Change | 6.08% | 6.67% | -84.17% |
| Total Long-Term Liabilities | $6.365M | $15.00M | $16.10M |
| YoY Change | -62.56% | -6.83% | -57.52% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $15.13M | $12.58M | $10.40M |
| Total Long-Term Liabilities | $6.365M | $15.00M | $16.10M |
| Total Liabilities | $28.82M | $27.58M | $26.50M |
| YoY Change | 3.77% | 4.08% | -56.98% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$247.3M | ||
| YoY Change | |||
| Common Stock | $335.6M | ||
| YoY Change | |||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $91.02M | $94.55M | $92.00M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $119.8M | $122.1M | $118.5M |
| YoY Change | 10.5% | 3.06% | -2.55% |
Cashflow Statement
| Concept | 2012 Q3 | 2012 Q2 | 2011 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$15.03M | -$13.77M | -$10.24M |
| YoY Change | 27.7% | 34.47% | 7.45% |
| Depreciation, Depletion And Amortization | $770.0K | $820.0K | $1.060M |
| YoY Change | -36.89% | -22.64% | -22.06% |
| Cash From Operating Activities | -$10.95M | -$11.96M | -$9.370M |
| YoY Change | 35.86% | 27.64% | -3.2% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$70.00K | -$80.00K | -$80.00K |
| YoY Change | -41.67% | 0.0% | -89.33% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $6.060M | $9.160M | -$25.74M |
| YoY Change | -42.12% | -135.59% | 47.34% |
| Cash From Investing Activities | $5.990M | $9.080M | -$25.82M |
| YoY Change | -42.13% | -135.17% | 41.79% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 9.580M | -1.300M | 35.88M |
| YoY Change | -48000.0% | -103.62% | 9342.11% |
| NET CHANGE | |||
| Cash From Operating Activities | -10.95M | -11.96M | -9.370M |
| Cash From Investing Activities | 5.990M | 9.080M | -25.82M |
| Cash From Financing Activities | 9.580M | -1.300M | 35.88M |
| Net Change In Cash | 4.620M | -4.180M | 690.0K |
| YoY Change | 103.52% | -705.8% | -102.51% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$10.95M | -$11.96M | -$9.370M |
| Capital Expenditures | -$70.00K | -$80.00K | -$80.00K |
| Free Cash Flow | -$10.88M | -$11.88M | -$9.290M |
| YoY Change | 37.03% | 27.88% | 4.03% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2011Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
5966000 | USD |
| CY2011Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2011Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
9093000 | USD |
| CY2011Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
44000 | USD |
| CY2011Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
271032000 | USD |
| CY2011Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
2652000 | USD |
| CY2011Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-205006000 | USD |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
68722000 | USD |
| CY2011Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
97994000 | USD |
| CY2011Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2012Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2011Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
24923000 | USD |
| CY2011Q4 | us-gaap |
Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
|
170000 | USD |
| CY2011Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1202000 | USD |
| CY2011Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
329000 | USD |
| CY2011Q4 | us-gaap |
Goodwill
Goodwill
|
8965000 | USD |
| CY2011Q4 | us-gaap |
Assets
Assets
|
97994000 | USD |
| CY2011Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
935000 | USD |
| CY2011Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
219000 | USD |
| CY2011Q4 | us-gaap |
Secured Debt Current
SecuredDebtCurrent
|
6136000 | USD |
| CY2011Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14298000 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11899000 | USD |
| CY2011Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
9008000 | USD |
| CY2011Q4 | us-gaap |
Assets Current
AssetsCurrent
|
54684000 | USD |
| CY2011Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7008000 | USD |
| CY2011Q4 | us-gaap |
Liabilities
Liabilities
|
29272000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4576000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
966000 | USD | |
| CY2012Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| cldx |
Revenue From Contracts And Grants
RevenueFromContractsAndGrants
|
149000 | USD | |
| CY2011Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-10222000 | USD |
| CY2011Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
15000 | USD |
| CY2011Q2 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-1000 | USD |
| CY2012Q2 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2012Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
3000000 | shares |
| CY2012Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2012Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
122129000 | USD |
| CY2012Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
94548000 | USD |
| CY2012Q2 | us-gaap |
Liabilities
Liabilities
|
27581000 | USD |
| CY2012Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12579000 | USD |
| CY2012Q2 | us-gaap |
Assets
Assets
|
122129000 | USD |
| CY2011Q2 | us-gaap |
Interest Expense
InterestExpense
|
434000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
920000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-20272000 | USD | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
28000 | USD | |
| us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-5000 | USD | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-20295000 | USD | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.58 | ||
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
163000 | USD | |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
24006000 | USD | |
| us-gaap |
Royalty Expense
RoyaltyExpense
|
4443000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14021000 | USD | |
| us-gaap |
Revenues
Revenues
|
4468000 | USD | |
| us-gaap |
Royalty Revenue
RoyaltyRevenue
|
4443000 | USD | |
| cldx |
Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
|
25000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-27219000 | USD | |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-27289000 | USD | |
| CY2011Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2012Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
USD | |
| CY2011Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
44210636 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44210636 | shares |
| CY2011Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
297000000 | shares |
| CY2011Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2011Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
3000000 | shares |
| CY2012Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
58753571 | shares |
| CY2012Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
58753571 | shares |
| CY2012Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
297000000 | shares |
| CY2012Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2011Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
| CY2011Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
79000 | USD |
| CY2011Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9881000 | USD |
| CY2011Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
11833000 | USD |
| CY2011Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2240000 | USD |
| CY2011Q2 | us-gaap |
Royalty Expense
RoyaltyExpense
|
1941000 | USD |
| CY2011Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7169000 | USD |
| CY2011Q2 | us-gaap |
Revenues
Revenues
|
1952000 | USD |
| CY2011Q2 | us-gaap |
Royalty Revenue
RoyaltyRevenue
|
1941000 | USD |
| CY2011Q2 | cldx |
Revenue From Product Development And Licensing Agreements
RevenueFromProductDevelopmentAndLicensingAgreements
|
11000 | USD |
| CY2012Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-13813000 | USD |
| CY2012Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-13488000 | USD |
| CY2012Q2 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
15497000 | USD |
| CY2012Q2 | us-gaap |
Revenues
Revenues
|
2009000 | USD |
| CY2012Q2 | cldx |
Revenue From Contracts And Grants
RevenueFromContractsAndGrants
|
96000 | USD |
| us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<table style="font-size:10pt; font-family:'Times New Roman',times,serif;"> <tr> <td> <p style="MARGIN: 0in 0in 0pt"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">(1)  Basis of Presentation</font></b></p> <p style="MARGIN: 0in 0in 0pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The accompanying unaudited condensed consolidated financial statements have been prepared by Celldex Therapeutics, Inc. (the “Company” or “Celldex”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and reflect the operations of the Company and its wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">These interim financial statements do not include all the information and footnotes required by U.S. GAAP for annual financial statements and should be read in conjunction with the audited financial statements for the year ended December 31, 2011, which are included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 8, 2012.  In the opinion of management, the interim financial statements reflect all normal recurring adjustments necessary to fairly state the Company’s financial position and results of operations for the interim periods presented.  The year-end consolidated balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future interim period or the fiscal year ending December 31, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">At June 30, 2012, the Company had cash, cash equivalents and marketable securities of $78.7 million; working capital of $67.8 million; and a Term Loan balance of $13.9 million. The Company incurred a loss of $27.3 million for the six months ended June 30, 2012.  Net cash used in operations for the six months ended June 30, 2012 was $25.5 million. The Company believes that the cash, cash equivalents and marketable securities at June 30, 2012 will be sufficient to meet estimated working capital requirements and fund planned operations for at least the next twelve months.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2"> </font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" size="2">The Company raised net proceeds of $51.9 million during the six months ended June 30, 2012 from the sale of its common stock.  During the next twelve months, the Company may take further steps to raise additional capital to meet its long-term liquidity needs.  These capital raising activities may include, but may not be limited to, one or more of the following: the licensing of technology programs with existing or new collaborative partners, possible business combinations, issuance of debt, or the issuance of common stock or other securities via private placements or public offerings. While the Company continues to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and the Company’s negotiating position in capital-raising efforts may worsen as existing resources are used. There is also no assurance that the Company will be able to enter into further collaborative relationships. Additional equity financing may be dilutive to the Company’s stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict the Company’s ability to operate as a business; and licensing or strategic collaborations may result in royalties or other terms which reduce the Company’s economic potential from products under development. If the Company is unable to raise the funds necessary to meet its long-term liquidity needs, it may have to delay or discontinue the development of one or more programs, discontinue or delay on-going or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or a part of the Company.</font></p></td></tr></table> | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
Celldex Therapeutics, Inc. | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000744218 | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2012-06-30 | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| CY2012Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
59292071 | shares |
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2012 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 |
